Identification of prognostic subgroups for overall survival in patients (pts) with BRAFV600-mutated metastatic melanoma treated with vemurafenib ± cobimetinib: a pooled exploratory analysis of the BRIM-2, BRIM-3, BRIM-7, and coBRIM studies

被引：0

作者：

Hauschild, A. ^{[1
]}

Larkin, J. ^{[2
]}

Ribas, A. ^{[3
]}

Dreno, B. ^{[4
]}

Flaherty, K. T. ^{[5
]}

Ascierto, P. A. ^{[6
]}

Lewis, K. D. ^{[7
]}

Mckenna, E. ^{[8
]}

Zhu, Q. ^{[8
]}

Mun, Y. ^{[8
]}

Mcarthur, G. A. ^{[9
,10
]}

机构：

[1] Univ Hosp Schleswig Holstein, Kiel, Germany

[2] Royal Marsden NHS Fdn Trust, London, England

[3] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA

[4] Nantes Univ, Nantes, France

[5] Massachusetts Gen Hosp, Boston, MA 02114 USA

[6] Fdn G Pascale, Ist Nazl Tumori, Naples, Italy

[7] Univ Colorado, Ctr Comprehens Canc, Aurora, CO USA

[8] Genentech Inc, San Francisco, CA 94080 USA

[9] Peter MacCallum Canc Ctr, East Melbourne, Australia

[10] Univ Melbourne, Parkville, Vic, Australia

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SY8-5

引用

页码：E1 / E2

页数：2